A trial of buparlisib for advanced hormone receptor positive breast cancer that is HER2 negative and has got worse despite having other treatments (BELLE 3)

This trial looked at buparlisib (BKM120) for breast cancer that had spread into tissue surrounding the breast or to another part of your body.

The trial was for women who had breast cancer that had got worse despite having a type of hormone therapy called an aromatase inhibitor as well as a drug called an mTOR inhibitor.

This trial was open for women to join between 2013 and 2016. These results were published in 2018.